Serum cytokeratin 19 fragments: a dedifferentiation marker in advanced thyroid cancer.

Détails

ID Serval
serval:BIB_F02C00498451
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Serum cytokeratin 19 fragments: a dedifferentiation marker in advanced thyroid cancer.
Périodique
European journal of endocrinology
Auteur(s)
Giovanella L., Treglia G., Verburg F.A., Salvatori M., Ceriani L.
ISSN
1479-683X (Electronic)
ISSN-L
0804-4643
Statut éditorial
Publié
Date de publication
12/2012
Peer-reviewed
Oui
Volume
167
Numéro
6
Pages
793-797
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: ppublish
Résumé
This study was undertaken to evaluate serum cytokeratin 19 fragment (Cyfra 21.1) expressions in patients with advanced thyroid carcinoma and to explore the relationship between serum Cyfra 21.1 and the degree of radioiodine ((131)I) avidity of thyroid carcinoma cells.
Enrolled were 76 consecutive patients with advanced thyroid carcinoma submitted to high-activity (131)I treatment. In each patient, serum thyroglobulin (Tg) and Cyfra 21.1 were measured before (131)I administration and compared with the posttreatment whole-body scan results.
Thirty-one (41%) of 76 patients had iodine-avid and 45 (59%) had iodine-refractory diseases respectively. Significantly higher serum Cyfra 21.1, but not Tg, levels were found in patients with (131)I-refractory disease compared with patients with iodine-avid disease (P<0.01).
This is the first report describing the potential role of serum Cyfra 21.1 as marker of dedifferentiation and resistance to (131)I therapy in patients with advanced thyroid carcinoma.

Mots-clé
Adult, Aged, Biomarkers, Tumor/blood, Female, Humans, Keratin-19/blood, Male, Middle Aged, Thyroglobulin/blood, Thyroid Neoplasms/blood
Pubmed
Web of science
Open Access
Oui
Création de la notice
20/08/2017 21:23
Dernière modification de la notice
09/05/2019 3:15
Données d'usage